A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy

BJU International

Volumn 104, Issue 8, 2009, Pages 1098-1102

  Barlow, Lamont ^a   McKiernan, James ^a   Sawczuk, Ihor ^b   Benson, Mitchell ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Docetaxel; Intravesical therapy; Novel therapeutics

Indexed keywords

BCG VACCINE; DOCETAXEL; INTERFERON; MITOMYCIN C;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER BIOPSY; BLADDER CANCER; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; DISEASE FREE INTERVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE CYTOLOGY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 70349329842     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08543.x     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Malkowicz SB. Management of superficial bladder cancer. In Walsh PC, Retik AB, Vaughan ED, Wein AJ, Campbell's Urology, Vol. 4. Philadelphia : WB Saunders, 2002 : 2785 2802
3. Crawford ED. Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 2002 20 : 3185 3186
4. Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol 1984 132 : 457 459
5. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000 163 : 1124 1129
6. Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 1992 147 : 1020 1023
7. Pansadoro V, Emiliozzi P, Defidio L et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 1995 154 : 2054 2058
8. Kim JC, Steinberg GD. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging 2001 18 : 335 344
9. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007 52 : 1123 1129
10. Lamm DL, O'Donnell MA, Genitourinary Oncology Study Group. Multicenter randomized comparison of BCG with or without alfa 2b interferon (IFN) and Oncovite (ONC) versus recommended daily allowance (RDA) vitamins during induction and extended 3-week maintenance. AUA Annual Meeting, 2008
11. de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998 78 : 1342 1345
12. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999 17 : 2341 2354
13. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 1512
14. McKiernan JM, Masson P, Murphy AM et al. Phase I: trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006 24 : 3075 80
15. Laudano MA, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM. Long term clinical outcome of a phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. AUA Annual Meeting 2008 May 18
16. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983 130 : 1083 1086
17. Skinner DG, Crawford ED, Kaufman JJ. Complications of radical cystectomy for carcinoma of the bladder. J Urol 1980 123 : 640 643
18. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987 137 : 220 224
19. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994 152 : 367 373
20. Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982 128 : 27 30
21. Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990 144 : 652 657
22. Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995 153 : 934 941
23. Oldbring J, Glifberg I, Mikulowski P, Hellsten S. Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. J Urol 1989 141 : 1311 1313
24. Sadek S, Soloway MS, Hook S, Civantos F. The value of upper tract cytology after transurethral resection of bladder tumor in patients with bladder transitional cell cancer. J Urol 1999 161 : 77 9
25. Shinka T, Uekado Y, Aoshi H, Hirano A, Ohkawa T. Occurrence of uroepithelial tumors of the upper urinary tract after the initial diagnosis of bladder cancer. J Urol 1988 140 : 745 748
26. Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996 156 : 1286 7
27. Miller EB, Eure GR, Schellhammer PF. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology 1993 42 : 26 30